Source: China – South China Morning PostShares in Jiangsu Hengrui Pharmaceuticals, China’s largest drug maker by market value, got a boost on Thursday after it announced its fifth licensing deal of the year, widening its access to the key emerging market of India.
The Shanghai-listed company, which went public in Hong Kong in May and raised HK$9.9 billion (US$1.26 billion), struck a deal with Glenmark Specialty of Mumbai-based Glenmark Pharmaceuticals, it said in a stock exchange filing late on Wednesday.
The agreement was part of an…Read More